Doximity DOCS recently announced an extension of its 13-year partnership with U.S. News & World Report, strengthening its role in helping patients find physicians and schedule appointments. The company will continue providing physician data for U.S. News' Doctor Finder, supporting its Patient Connect appointment-booking tools. DOCS will also continue to serve as the exclusive third-party provider of the Expert Opinion physician survey used in the Best Hospitals and Best Children's Hospitals rankings.
Per management, Doximity leverages its network of more than 3 million medical professionals across specialties and treatment areas to help Americans identify and connect with appropriate healthcare providers. The company is pleased to extend its strategic partnership with U.S. News & World Report to further support patients in navigating their healthcare needs.
DOCS Stock Trend Following the News
DOCS stock has lost 2.1% since the announcement on Tuesday. Year to date, the stock has declined 32.4% against the industry’s 17.8% growth and the S&P 500’s 12.5% rise.
The extended agreement could support DOCS' growth by reinforcing its relationships with major healthcare information platforms and hospital partners. Continued integration of Doximity's physician data and appointment-booking technology may strengthen demand for its digital solutions while helping hospitals attract patients. The partnership also reinforces the value of Doximity's extensive physician database, creating opportunities to expand its hospital-facing services and deepen its role in the patient acquisition process.
DOCS currently has a market capitalization of $5.45 billion.
Image Source: Zacks Investment Research
More on the News
Doximity will continue supporting three key U.S. News offerings. Its physician data powers Doctor Finder, which helps patients identify doctors and book appointments with hospital partners. Its Patient Connect product enables appointment scheduling and links patients directly to participating healthcare providers. Doximity will also remain the exclusive third-party provider of the Expert Opinion physician survey, which contributes to U.S. News' hospital rankings.
The extended partnership strengthens Doximity’s role as a data provider for U.S. News’ physician- and hospital-facing products, combining U.S. News’ independent rankings and healthcare platform with Doximity’s physician network, data and technology. With over 65 million Americans using U.S. News annually to research healthcare options, the collaboration helps connect patients' care decisions with practical next steps, including finding physicians and scheduling appointments with participating hospitals.
Industry Prospects Favoring the Market
According to Precedence Research, the U.S. patient referral management software market was valued at $5.82 billion in 2025 and is projected to witness a CAGR of 17% from 2026 to 2035.
Factors like a large healthcare ecosystem of healthcare providers, rising demand for integrated referral solutions, widespread EHR adoption and CMS and ONC initiatives promoting interoperability and seamless data exchange are boosting market growth.
Other News
Doximity recently announced that it has become a founding partner in Fireworks’ Specialized Intelligence Index, featuring leading AI benchmarks across healthcare, law and customer support. The company is also launching its open-source Bedside Bench to evaluate clinical AI performance in real-world medical scenarios. Independently graded by Fireworks, Doximity Ask ranked first against leading frontier models.
Doximity, Inc. Price
Doximity, Inc. price | Doximity, Inc. Quote
DOCS’ Zacks Rank & Key Picks
Currently, Doximity carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Merit Medical Systems MMSI.
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Doximity, Inc. (DOCS): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
OPKO Health, Inc. (OPK): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).